Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00148603 · ClinicalTrials.gov registry record · NA
Montelukast in the Treatment of Duodenal Eosinophilia
A NA study, sponsored by Children's Mercy Hospital Kansas City.
- Completed
- Registry status
- NA
- Development phase
- 24
- Enrollment target
NCT00148603 is a NA study that has completed, run by Children's Mercy Hospital Kansas City. The registered enrollment target is 24 participants.
The verdict
NCT00148603, a NA study, has completed, sponsored by Children's Mercy Hospital Kansas City.
- COMPLETED
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
Study Summary
This is a single site study of the effect of montelukast on eosinophil and mast cell counts and activation in the lining of the duodenum in 24 children with dyspepsia in association with duodenal eosinophilia in association with measuring the concentration of the medication in the lining of the duodenum. Patients will be endoscoped with biopsies obtained from the duodenum as part of routine clinical care. Participants in the study will then receive montelukast daily and the endoscopy with biopsies will be repeated on day 21 to measure cell counts and activation and tissue montelukast levels. Cell counts and measures of activation will be compared to pre-treatment levels.
Interventions
- DRUG montelukast
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2005-09 |
| Est. Completion | 2006-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00148603
The ClinicalTrials.gov registry entry for NCT00148603 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Mercy Hospital Kansas City, which has 184 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which montelukast is the first listed.
NCT00148603 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00148603 about?
NCT00148603 is a clinical study titled "Montelukast in the Treatment of Duodenal Eosinophilia". This is a single site study of the effect of montelukast on eosinophil and mast cell counts and activation in the lining of the duodenum in 24 children with dyspepsia in association with duodenal eosinophilia in association with measuring the concentration of the medication in the lining of the duod...
What is the current status of trial NCT00148603?
This trial is currently completed. It is a NA study. The enrollment target is 24 participants. The study started on 2005-09. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00148603?
The interventions under investigation include: montelukast (DRUG).
Who is sponsoring clinical trial NCT00148603?
This trial is sponsored by Children's Mercy Hospital Kansas City, which has 184 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.